S Heptinstall

Summary

Affiliation: University of Nottingham
Country: UK

Publications

  1. ncbi request reprint Adenine nucleotide metabolism in human blood--important roles for leukocytes and erythrocytes
    S Heptinstall
    Centre for Integrated Systems Biology and Medicine, Institute of Clinical Research, University of Nottingham, UK
    J Thromb Haemost 3:2331-9. 2005
  2. ncbi request reprint Variable therapeutic effectiveness of clopidogrel in acute coronary syndromes
    S Heptinstall
    Cardiovascular Medicine, Centre for Integrated Systems Biology and Medicine, University of Nottingham, Nottingham, UK
    J Thromb Haemost 4:539-41. 2006
  3. ncbi request reprint Cocoa flavanols and platelet and leukocyte function: recent in vitro and ex vivo studies in healthy adults
    Stan Heptinstall
    Cardiovascular Medicine, University of Nottingham, UK
    J Cardiovasc Pharmacol 47:S197-205; discussion S206-9. 2006
  4. doi request reprint DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease
    Stan Heptinstall
    Department of Cardiovascular Medicine, University of Nottingham, Nottingham, UK
    Platelets 19:605-13. 2008
  5. doi request reprint Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents
    P Manolopoulos
    Centre for Integrated Systems Biology and Medicine, School of Medical and Surgical Sciences, Nottingham, UK
    Platelets 19:134-45. 2008
  6. doi request reprint Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers
    S C Fox
    Department of Cardiovascular Medicine, School of Clinical Sciences, University of Nottingham, Nottingham, UK
    Platelets 24:392-400. 2013
  7. ncbi request reprint Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1
    S C Fox
    Cardiovascular Medicine, University Hospital, Queen s Medical Centre, University of Nottingham, Nottingham, UK
    Cell Calcium 35:39-46. 2004
  8. doi request reprint The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function
    N L Dovlatova
    Cardiovascular Medicine, University of Nottingham, Nottingham, UK
    J Thromb Haemost 6:1153-9. 2008
  9. doi request reprint Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin
    S C Fox
    Cardiovascular Medicine, Queens Medical Centre, Nottingham, UK
    Platelets 20:250-9. 2009
  10. ncbi request reprint Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists
    R F Storey
    Department of Cardiovascular Medicine, University Hospital, Queen s Medical Centre, Nottingham, UK
    Circulation 98:1616-21. 1998

Collaborators

Detail Information

Publications37

  1. ncbi request reprint Adenine nucleotide metabolism in human blood--important roles for leukocytes and erythrocytes
    S Heptinstall
    Centre for Integrated Systems Biology and Medicine, Institute of Clinical Research, University of Nottingham, UK
    J Thromb Haemost 3:2331-9. 2005
    ....
  2. ncbi request reprint Variable therapeutic effectiveness of clopidogrel in acute coronary syndromes
    S Heptinstall
    Cardiovascular Medicine, Centre for Integrated Systems Biology and Medicine, University of Nottingham, Nottingham, UK
    J Thromb Haemost 4:539-41. 2006
  3. ncbi request reprint Cocoa flavanols and platelet and leukocyte function: recent in vitro and ex vivo studies in healthy adults
    Stan Heptinstall
    Cardiovascular Medicine, University of Nottingham, UK
    J Cardiovasc Pharmacol 47:S197-205; discussion S206-9. 2006
    ..The research suggests that the consumption of certain cocoa products may provide a dietary approach to maintaining or improving cardiovascular health...
  4. doi request reprint DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease
    Stan Heptinstall
    Department of Cardiovascular Medicine, University of Nottingham, Nottingham, UK
    Platelets 19:605-13. 2008
    ..DG-041 remained effective in the presence of a P2Y(12) antagonist and aspirin. DG-041 warrants continued investigation as a potential agent for the treatment of atherothrombosis without inducing unwanted bleeding risk...
  5. doi request reprint Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents
    P Manolopoulos
    Centre for Integrated Systems Biology and Medicine, School of Medical and Surgical Sciences, Nottingham, UK
    Platelets 19:134-45. 2008
    ..The results are discussed in relation to the possibility that acyl-CoAs may contribute as endogenous modulators of platelet function and might serve as lead compounds for the design of novel antithrombotics...
  6. doi request reprint Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers
    S C Fox
    Department of Cardiovascular Medicine, School of Clinical Sciences, University of Nottingham, Nottingham, UK
    Platelets 24:392-400. 2013
    ..In both in-vitro and ex-vivo studies, aspirin neither promoted nor negated the effects of the other drugs. ..
  7. ncbi request reprint Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1
    S C Fox
    Cardiovascular Medicine, University Hospital, Queen s Medical Centre, University of Nottingham, Nottingham, UK
    Cell Calcium 35:39-46. 2004
    ..This would contribute to the effectiveness of P2Y(12) antagonists as antithrombotic agents in man...
  8. doi request reprint The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function
    N L Dovlatova
    Cardiovascular Medicine, University of Nottingham, Nottingham, UK
    J Thromb Haemost 6:1153-9. 2008
    ..At the cessation of cangrelor infusion, patients are likely to receive clopidogrel or prasugrel as a means of maintaining antiplatelet therapy...
  9. doi request reprint Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin
    S C Fox
    Cardiovascular Medicine, Queens Medical Centre, Nottingham, UK
    Platelets 20:250-9. 2009
    ..It is concluded that measurements of P-selectin performed on fixed blood samples following platelet stimulation in whole blood in a remote setting can be used effectively to monitor the effects of clopidogrel and aspirin...
  10. ncbi request reprint Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists
    R F Storey
    Department of Cardiovascular Medicine, University Hospital, Queen s Medical Centre, Nottingham, UK
    Circulation 98:1616-21. 1998
    ..We compared PRP turbidimetry, as a measure of macroaggregate formation, with single-platelet counting in both whole blood and PRP as a measure of microaggregate formation, using both citrate and hirudin anticoagulation...
  11. ncbi request reprint Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood
    H M Sanderson
    Department of Medicine, University Hospital, Nottingham, UK
    Blood Coagul Fibrinolysis 7:245-8. 1996
    ..This is consistent with these platelet responses to ADP being mediated by different receptors, with P2T receptors mediating only the aggregation response...
  12. ncbi request reprint Quantitation of platelet aggregation and microaggregate formation in whole blood by flow cytometry
    S C Fox
    Cardiovascular Medicine, University Hospital, Queen s Medical Centre, Nottingham NG7 2UH, UK
    Platelets 15:85-93. 2004
    ..Assessment of single platelet loss by flow cytometry was found to be a reliable way of monitoring aggregation responses and provided new information on rapid microaggregate formation in ADP-stimulated blood...
  13. doi request reprint Raised levels of CD39 in leucocytosis result in marked inhibition of ADP-induced platelet aggregation via rapid ADP hydrolysis
    J R Glenn
    Cardiovascular Medicine, University of Nottingham, Nottingham, UK
    Platelets 19:59-69. 2008
    ..It is concluded that ADP-induced platelet aggregation in leucocytosis is reduced as a result of enhanced ADP metabolism due to raised levels of leucocyte-associated CD39...
  14. ncbi request reprint Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood
    R F Storey
    Cardiovascular Medicine, University Hospital, Queen s Medical Centre, Nottingham, NG7 2UH, UK
    Platelets 12:443-7. 2001
    ....
  15. ncbi request reprint Platelet reactivity in vitro in relation to thromboxane in healthy pregnancy
    E H Horn
    Division of Therapeutics, University Hospital, Nottingham, UK
    Thromb Haemost 75:346-51. 1996
    ..In conclusion, platelets are more sensitive to the activating effects of thromboxane during pregnancy, but there is no change in the intrinsic reactivity of the thromboxane biosynthetic pathway...
  16. ncbi request reprint A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies
    R F Storey
    Division of Cardiovascular Medicine, University Hospital, Nottingham, UK
    Thromb Haemost 82:1307-11. 1999
    ..WBSPC was most discriminating at high levels of inhibition and offered a rapid means of monitoring GPIIb/IIIa antagonist effect within the therapeutic range of inhibition...
  17. ncbi request reprint Interactions of platelets with Synthocytes, a novel platelet substitute
    A R Davies
    Centre for Vascular Research, University of Nottingham, Cardiovascular Medicine, Queen s Medical Centre, Nottingham NG7 2UH, UK
    Platelets 13:197-205. 2002
    ..It is considered likely that in the clinical setting of thrombocytopenia any interaction between Synthocytes and residual platelets that are present may contribute to primary haemostasis...
  18. ncbi request reprint Platelet aggregation and intracellular calcium mobilisation responses are enhanced by cyclosporin A but not by pimecrolimus (SDZ ASM 981)
    S C Fox
    Centre for Vascular Research, University of Nottingham, Cardiovascular Medicine, Queen s Medical Centre, Nottingham NG7 2UH, UK
    Platelets 13:213-8. 2002
    ..Enhanced platelet aggregation responses to ADP observed in the presence of cyclosporin A may be a consequence of enhanced ADP-induced calcium mobilisation...
  19. doi request reprint Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function
    David Iyu
    Cardiovascular Medicine, Queen s Medical Centre, Nottingham, UK
    Thromb Haemost 105:96-106. 2011
    ..The effects of cangrelor, ticagrelor and prasugrel on platelet function are mediated mainly through P2Y(12)receptors and not through another G-protein-coupled receptor...
  20. ncbi request reprint 'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists
    J R Glenn
    Jacqueline Glenn, Cardiovascular Medicine, University Hospital, Queen s Medical Centre, Nottingham, NG7 2UH, UK, Tel 44 115 8231012, Fax 44 115 8231017, E mail
    Thromb Haemost 111:539-48. 2014
    ..The latter confers a distinct advantage over existing methods used to monitor effects of P2Y12 antagonists on platelet function. ..
  21. ncbi request reprint Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders
    N Dovlatova
    Cardiovascular Medicine, University of Nottingham, Queens Medical Centre, Nottingham, UK Centre for Cardiovascular Sciences, Birmingham Platelet Group, University of Birmingham, Birmingham, UK
    J Thromb Haemost 12:660-5. 2014
    ..Furthermore, many subjects with suspected PFDs do not show a platelet abnormality on LTA...
  22. ncbi request reprint Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes
    Miles W H Behan
    Division of Cardiovascular Medicine, Queens Medical Centre, Nottingham NG7 2UH, UK
    Platelets 16:73-80. 2005
    ..The results provide new information on the mechanisms involved in the beneficial effects of P2Y(12) antagonists in patients with ACS...
  23. ncbi request reprint Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin
    Robert F Storey
    Cardiovascular Medicine, University Hospital, Queen s Medical Centre, Nottingham, UK
    Thromb Haemost 88:488-94. 2002
    ..These effects of clopidogrel and AR-C69931MX may confer therapeutic benefits in the management of acute coronary syndromes...
  24. ncbi request reprint The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro
    Thomas Scholz
    Centre for Vascular Biology and Medicine, University Hospital Jena, Nordhäuser Str 78, D 99089 Erfurt, Germany
    Platelets 13:401-6. 2002
    ..The augmented P/M formation and monocyte TF expression in the presence of a GPIIb/IIIa antagonist may be relevant to the poor antithrombotic efficiency of oral GPIIb/IIIa antagonists as shown in recent large clinical trials...
  25. ncbi request reprint Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease
    Robert F Storey
    Cardiovascular Medicine, University Hospital, Queen s Medical Centre, Nottingham, NG7 2UH, UK
    Platelets 13:407-13. 2002
    ..In conclusion, therapeutic administration of clopidogrel moderately inhibits platelet P2Y(12) receptor activation and substantially greater P2Y(12) receptor blockade can be achieved with AR-C69931MX...
  26. ncbi request reprint Transfer of tissue factor from platelets to monocytes: role of platelet-derived microvesicles and CD62P
    Thomas Scholz
    Friedrich Schiller University of Jena, Centre for Vascular Biology and Medicine, Erfurt, Germany
    Thromb Haemost 88:1033-8. 2002
    ..The interaction of platelet-derived microvesicles with monocytes and the transfer of TF to monocytes strongly depend on CD62P...
  27. ncbi request reprint The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions
    Lian Zhao
    Centre for Vascular Research, University of Nottingham, UK
    Curr Med Res Opin 19:178-86. 2003
    ..The Asp/Dip/AR-C was superior to abciximab and MK-852 in inhibiting platelet and leukocyte function...
  28. doi request reprint Multiple electrode aggregometry and P2Y(12) antagonists
    Andrew Johnson
    Thromb Haemost 99:1127-9. 2008
  29. ncbi request reprint Mechanisms involved in adenosine triphosphate--induced platelet aggregation in whole blood
    Nicholas P Stafford
    Centre for Integrated Systems Biology and Medicine, University of Nottingham, UK
    Arterioscler Thromb Vasc Biol 23:1928-33. 2003
    ..In this study we report on the effects of ATP on platelet aggregation in whole blood...
  30. ncbi request reprint P-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist
    Lian Zhao
    Centre for Integrated Systems Biology and Medicine and Institute of Neuroscience, University of Nottingham, UK
    Platelets 14:473-80. 2003
    ..Pro-inflammatory and pro-thrombotic effects of CD40L and tissue factor may be an explanation of the negative clinical effects using GPIIb/IIIa antagonists...
  31. ncbi request reprint Platelet-monocyte interaction and GPIIb/IIIa blockade
    Lian Zhao
    Thromb Haemost 92:888-90. 2004
  32. ncbi request reprint Enhanced platelet aggregation and activation under conditions of hypothermia
    Ruben G Xavier
    Thrombosis and Haemostasis Group, Cardiovascular Medicine, University of Nottingham, Nottingham, UK
    Thromb Haemost 98:1266-75. 2007
    ..Overall, our results demonstrate an enhancement of platelet function at 28 degrees C compared with 37 degrees C, particularly in the presence of ADP...
  33. ncbi request reprint Clopidogrel resistance
    Stan Heptinstall
    Catheter Cardiovasc Interv 63:397-8. 2004
  34. ncbi request reprint Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin
    Steen Husted
    Department of Medicine and Cardiology, Arhus University Hospital, Denmark
    Eur Heart J 27:1038-47. 2006
    ..This double-blind, parallel-group study was conducted to assess the pharmacodynamics, pharmacokinetics, and safety of AZD6140, the first oral, reversible adenosine diphosphate (ADP) receptor antagonist...
  35. ncbi request reprint Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke
    Lian Zhao
    Clinical Research, University of Nottingham, Nottingham, UK
    Platelets 17:100-4. 2006
    ..In particular, dipyridamole reduces plasma vWf and clopidogrel lowers plasma PAI-1 levels. These effects may explain, in part, their roles in preventing atherothrombogenesis...
  36. ncbi request reprint Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin
    Robert F Storey
    Cardiovascular Research Unit, Clinical Sciences Centre, Northern General Hospital, Sheffield S5 7AU, UK
    Thromb Res 115:301-7. 2005
    ..We assessed the ability of cangrelor, a selective P2Y12 antagonist, A2P5P, a selective P2Y1 antagonist, and aspirin to block the potentiating effects of heparin...
  37. ncbi request reprint Leukocytosis, vascular disease, and adenine nucleotide metabolism
    Stan Heptinstall
    Arterioscler Thromb Vasc Biol 26:e22-3. 2006